Management of Clostridioides difficile Infection in Patients with Chronic Kidney Disease

Diagnosis and Treatment

The Infectious Diseases Society of America recommends testing for C. difficile toxins immediately if the patient has antibiotic-associated diarrhea, as metronidazole use itself is a risk factor for CDI 4, 5, 6, 1
CDI should be suspected with recent antibiotic exposure, healthcare contact, or persistent diarrhea (≥3 unformed stools in 24 hours) 6, 1
The American College of Gastroenterology recommends oral vancomycin 125 mg four times daily for 10 days as the preferred treatment for CDI, even in patients with renal impairment 1, 2, 3
Severe CDI indicators include white blood cell count >15,000 cells/µL, serum creatinine >1.5 mg/dL or >50% above baseline, marked abdominal tenderness or distension, pseudomembranous colitis on endoscopy, and toxic megacolon or ileus on imaging 6, 1

The National Kidney Foundation advises avoiding metronidazole during intercurrent illness in CKD patients to prevent further kidney damage 4
Metronidazole 500 mg orally three times daily may be considered only if vancomycin is unavailable, and only in non-dialysis CKD patients 1, 3
Fidaxomicin 200 mg twice daily for 10 days is an alternative treatment for severe CDI 1, 5
Vancomycin 500 mg via nasogastric tube four times daily or as retention enema (500 mg in 100 mL normal saline every 4-12 hours) may be used in patients unable to take oral medications 6, 5

Cumulative and potentially irreversible neurotoxicity occurs with repeated or prolonged metronidazole courses, particularly in renal impairment 1, 2, 3, 4
Monitor serum creatinine daily until stable in CKD patients with diarrhea 4
Assess for peripheral neuropathy, ataxia, or encephalopathy during metronidazole therapy 4
Target urine output >0.5 mL/kg/hour as a marker of adequate renal perfusion 4
Replace electrolytes (potassium, magnesium) based on laboratory results 4